Breaking news
Circadian Gene Expression Variation Across Tissue Types May Offer Aging, Disease Clues
With a new computational approach, researchers profiled gene expression rhythms in dozens of tissues from more than 900 individuals for the Genotype-Tissue Expression project.
White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds
A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.
Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care
In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.
Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk
Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.
Siemens Healthineers Q1 Dx Revenues Fall 21 Percent; Firm Strikes Lab Analyzer Deal With Unilabs
A decline in demand for rapid COVID-19 antigen tests dragged on the company's diagnostics division while lockdowns in China reduced routine testing.
Becton Dickinson Fiscal Q1 Revenues Down 3 Percent; Firm Raises FY23 Guidance
The Franklin Lakes, New Jersey-based firm saw a 17 percent decline in its life sciences business due to an expected drop in COVID-19 testing.
Roche Diagnostics Revenues Essentially Flat in 2022
Molecular lab revenues fell 17 percent during the year, while core lab sales were up 3 percent and point-of-care revenues grew 15 percent.
NanoString Technologies, Weill Cornell Medicine Collaborate on Spatial Atlas of Human Tissues
Shares of the Seattle-based genomics firm rose as much as 9 percent in Thursday morning trading on the Nasdaq and were up 12 percent over the last two days.
Bio-Techne Fiscal Q2 Revenues Inch up as Protein Business Lags but Genomics Boom
The company reported 1 percent growth in revenues compared to Q2 2022 but said organic revenue growth was 4 percent.
Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug
The companies will jointly develop and commercialize Guardant360 CDx and Guardant360 TissueNext for taletrectinib treatment in advanced and metastatic NSCLC.